PFG
XLO icon

Pinnacle Financial Group’s Xilio Therapeutics XLO Stock Holding History

Pinnacle Financial Group’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-714
Closed -$6.4K – 119
2025
Q4 		$6.4K Hold
714
– – ﹤0.01% 112
2025
Q3 		$8.43K Hold
714
– – ﹤0.01% 108
2025
Q2 		$6.8K Hold
714
– – ﹤0.01% 101
2025
Q1 		$7.24K Hold
714
– – ﹤0.01% 95
2024
Q4 		$9.55K Hold
714
– – ﹤0.01% 84
2024
Q3 		$7.88K Hold
714
– – ﹤0.01% 80
2024
Q2 		$9.47K Buy
+714
New +$11.2K ﹤0.01% 71

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pinnacle Financial Group's XLO Position: Q1 2026 in Review

Pinnacle Financial Group sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 714 shares — an estimated $6.4K sold.

Pinnacle Financial Group first reported a position in XLO in Q2 2024 and held it in 7 quarters. The position peaked at $9.55K in Q4 2024. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Pinnacle Financial Group reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Pinnacle Financial Group sold 714 Xilio Therapeutics shares in Q1 2026, an estimated $6.4K.
  • Pinnacle Financial Group first reported a position in Xilio Therapeutics in Q2 2024 and held it in 7 quarters.
  • Pinnacle Financial Group's Xilio Therapeutics position peaked at $9.55K in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Pinnacle Financial Group's 13F filing for Q1 2026, filed 13 May 2026.